Scarica l'app Stockscreener
318.85
3.01%
-9.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$328.73
Aprire:
$323.03
Volume 24 ore:
872.42K
Relative Volume:
0.65
Capitalizzazione di mercato:
$42.29B
Reddito:
$3.71B
Utile/perdita netta:
$313.75M
Rapporto P/E:
141.27
EPS:
2.2571
Flusso di cassa netto:
$465.38M
1 W Prestazione:
-2.84%
1M Prestazione:
-1.91%
6M Prestazione:
-30.83%
1 anno Prestazione:
+19.50%
Intervallo 1D:
$315.89
$325.49
Intervallo di 1 settimana:
$314.20
$335.48
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Aberdeen Group plc Has $52.83 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
10 Best Future Stocks to Buy for the Next 5 Years - Insider Monkey
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 - Insider Monkey
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26 - simplywall.st
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price - Sahm
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Combines Strong Growth with a Technical Breakout Setup - ChartMill
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now - insidermonkey.com
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Alnylam (ALNY) Highlights Breakthrough Vutrisiran Data at ACC An - GuruFocus
Alnylam's (ALNY) Zilebesiran Shows Promising Phase 2 Safety Data - GuruFocus
Alnylam presents cardiovascular data at ACC conference - Investing.com
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management - Business Wire
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $360 - Moomoo
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy Recommendation - MSN
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY) - simplywall.st
How Alnylam Pharmaceuticals Inc. (ALNY) Affects Rotational Strategy Timing - Stock Traders Daily
Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
The European Commission Approves Alnylam’s AMVUTTRA - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR FranchiseSlideshow (NASDAQ:ALNY) 2026-03-26 - Seeking Alpha
3 Stocks Trading Below Estimated Intrinsic Value By Up To 46.8% - simplywall.st
Vanguard amends 13G/A; reports 0 shares in Alnylam (ALNY) - Stock Titan
H.C. Wainwright reiterates Alnylam stock rating at buy, $510 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - theglobeandmail.com
SG Americas Securities LLC Buys 59,071 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies - Insider Monkey
Avidity Partners Management LP's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam (ALNY) jumps 6.7% as investors refocus on TTR franchise after company webinar - Quiver Quantitative
Chardan Capital Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
ALNY: HC Wainwright & Co. Reiterates Buy Rating with $510 Target - gurufocus.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC Wainwright - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - simplywall.st
Alnylam Ties AI Partnerships To ATTR CM Growth And Access Story - Yahoo Finance
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Narrow-Moat Alnylam's Growth Driven By Strong Demand For Amvuttra in ATTR-CM - Morningstar
Immutrin raises $87M to advance drug for progressive heart disease - BioPharma Dive
Morgan Stanley reiterates Alnylam stock Equalweight rating at $360 - Investing.com
Alnylam Pharmaceuticals Touts AMVUTTRA ATTR-CM Momentum, Raises 2026 TTR Revenue Outlook - MarketBeat
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association - Business Wire
Viz.ai Partners with Alnylam Pharmaceuticals to Advance Earlier Identification and Care Coordination in Cardiac Amyloidosis - Business Wire
Alnylam partners with Viz.ai, AHA on ATTR-CM diagnosis efforts - Investing.com
Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Hudson Bay Capital Management LP Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Chart Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividend2026 EndofYear Setup & Weekly High Return Forecasts - baoquankhu1.vn
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
21,097 |
| Greenstreet Yvonne | Chief Executive Officer |
Mar 04 '26 |
Sale |
323.08 |
2,933 |
947,581 |
95,695 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,468 |
797,351 |
61,805 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
34,297 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 05 '26 |
Sale |
323.98 |
658 |
213,177 |
20,569 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 04 '26 |
Sale |
323.08 |
633 |
204,508 |
21,227 |
0.44%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):